Hematologic Malignancy
B Lymphoblastic Leukemia/Lymphoma
CI-CAN-00000469Explore in graph →
Hematologic163 active trials1 approved drugs180 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000469Explore in graph →
Clinical trials
373 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (49)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07570173 | A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) | recruiting | Phase 2 / Phase 3 | 340 | Merck Sharp & Dohme LLCINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT02003222 | Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia | active not recruiting | Phase 3 | 488 | National Cancer Institute (NCI)NIH | 4 | Sep 21, 2026 |
| NCT07223021 | A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia | recruiting | Phase 3 | 130 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Sep 17, 2026 | clinicaltrials |
| NCT04094311 | Study of Out of Specification for Tisagenlecleucel | recruiting | Phase 3 | 200 | Novartis PharmaceuticalsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT03150693 | Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | recruiting | Phase 3 | 303 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT04530565 | Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults | active not recruiting | Phase 3 | 348 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2026 | clinicaltrials |
| NCT03959085 | Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | recruiting | Phase 3 | 5,951 | Children's Oncology GroupNETWORK | 5 | Aug 25, 2026 | clinicaltrials |
| NCT05602194 | Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | active not recruiting | Phase 3 | 440 | Children's Oncology GroupNETWORK | 2 | Aug 21, 2026 | clinicaltrials |
| NCT03007147 | Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | active not recruiting | Phase 3 | 352 | Children's Oncology GroupNETWORK | 19 | Aug 19, 2026 | clinicaltrials |
| NCT07754682 | Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma(PREV-CART) | not yet recruiting | Phase 3 | 228 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Aug 10, 2026 | clinicaltrials |
| NCT03914625 | A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia | active not recruiting | Phase 3 | 6,720 | National Cancer Institute (NCI)NIH | 5 | Jul 30, 2026 | clinicaltrials |
| NCT02101853 | Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 3 | 669 | National Cancer Institute (NCI)NIH | 5 | Jul 29, 2026 | clinicaltrials |
| NCT06764238 | Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol(CCCG-I/HR-ALL) | recruiting | Phase 2 / Phase 3 | 1,800 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 2 | Jul 23, 2026 | clinicaltrials |
| NCT02883049 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations | completed | Phase 3 | 5,949 | National Cancer Institute (NCI)NIH | 7 | Jun 2, 2026 | clinicaltrials |
| NCT01190930 | Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma | completed | Phase 3 | 9,350 | Children's Oncology GroupNETWORK | 7 | May 28, 2026 | clinicaltrials |
| NCT07502118 | NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)(NexCAR19) | recruiting | Phase 2 / Phase 3 | 40 | Health Institutes of TurkeyOTHER_GOV | 1 | Mar 30, 2026 | clinicaltrials |
| NCT07476729 | International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) | not yet recruiting | Phase 3 | 750 | Charite University, Berlin, GermanyOTHER | 20 | Mar 17, 2026 | clinicaltrials |
| NCT07441291 | CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT | recruiting | Phase 3 | 70 | Peking University People's HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06882057 | Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol(CCCG-LR-B-ALL) | recruiting | Phase 2 / Phase 3 | 3,000 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 2 | Aug 26, 2025 | clinicaltrials |
| NCT03937544 | Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL | recruiting | Phase 2 / Phase 3 | 10 | National University of MalaysiaOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT04722848 | Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | active not recruiting | Phase 3 | 236 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06607419 | Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia(BBClean) | recruiting | Phase 2 / Phase 3 | 90 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 23, 2024 | clinicaltrials |
| NCT00381680 | Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia | completed | Phase 3 | 275 | Children's Oncology GroupNETWORK | 4 | Mar 26, 2024 | clinicaltrials |
| NCT04375683 | Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL | unknown | Phase 3 | 28 | Zhongda HospitalOTHER | 1 | Mar 24, 2022 | clinicaltrials |
| NCT00103285 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 3 | 5,377 | Children's Oncology GroupNETWORK | 5 | Jun 14, 2021 | clinicaltrials |
| NCT00075725 | Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia | completed | Phase 3 | 3,154 | Children's Oncology GroupNETWORK | 5 | Apr 27, 2021 | clinicaltrials |
| NCT00671034 | Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia | completed | Phase 3 | 166 | Children's Oncology GroupNETWORK | 1 | Apr 27, 2021 | clinicaltrials |
| NCT00720109 | Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 2 / Phase 3 | 63 | National Cancer Institute (NCI)NIH | 5 | Apr 13, 2020 | clinicaltrials |
| NCT00382109 | Tacrolimus and Methotrexate With or Without Sirolimus in Preventing Graft-Versus-Host Disease in Young Patients Undergoing Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia in Complete Remission | completed | Phase 3 | 146 | Children's Oncology GroupNETWORK | 3 | Aug 7, 2019 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials